Evidence map›Paper›PMID 33165751›Full record

ArticleTargeted oncology2021

Developing Symptom Lists for People with Cancer Treated with Targeted Therapies.

Samantha C Sodergren, Sally J Wheelwright, Deborah Fitzsimmons, Fabio Efficace, Mirjam Sprangers, Peter Fayers, Amelie Harle, Heike Schmidt, Andrew Bottomley, Anne-Sophie Darlington and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Samantha C SodergrenSchool of Health Sciences, University of Southampton, Southampton, UK.
Sally J WheelwrightSchool of Health Sciences, University of Southampton, Southampton, UK.
Deborah FitzsimmonsPublic Health, Policy and Social Sciences, University of Swansea, Swansea, UK.
Fabio EfficaceItalian Group for Adult Hematologic Disease (GIMEMA), Rome, Italy.
Mirjam SprangersDepartment of Medical Psychology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Peter FayersMedical Science and Nutrition, Aberdeen University School of Medicine, Aberdeen, UK.
Amelie HarlePoole Hospital NHS Foundation Trust, Poole, UK.
Heike SchmidtMartin Luther University Halle-Wittenberg, Halle, Germany.
Andrew BottomleyEORTC Quality of Life Department, Brussels, Belgium.
Anne-Sophie DarlingtonSchool of Health Sciences, University of Southampton, Southampton, UK.
Charlotte BensonThe Royal Marsden NHS Foundation Trust, Sutton, UK.
Anne BredartInstitut Curie, Paris, France.
Leopold HentschelUniversity Hospital Carl Gustav Carus, Dresden, Germany.
Juan Ignacio ArrarasComplejo Hospitalario de Navarra, Navarra, Spain.
Georgios IoannidisNicosia General Hospital, Nicosia, Cyprus.
Michael LeahyThe Christie NHS Foundation Trust, Manchester, UK.
Iwona LugowskaMaria Sklodowska-Curie Memorial Cancer Centre-Institute of Oncology, Warsaw, Poland.
Ourania Nicolatou-GalitisNational & Kapodistrian University of Athens, Athens, Greece.
Duska PetranovicUniversity Clinical Hospital Center Rijeka, Rijeka, Croatia.
Gudrun E RohdeFaculty of Health and Sport Sciences, University of Adger, Agder, Norway.
Vasilis VassiliouBank of Cyprus Oncology Centre, Nicosia, Cyprus.
Colin D JohnsonCancer Sciences, University of Southampton, Southampton, UK. c.d.johnson@soton.ac.uk.
EORTC Quality of Life Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTargeted therapies (TTs) have revolutionised cancer treatment with their enhanced specificity of action. Compared with conventional therapies, TTs are delivered over a longer period and often have unusual symptom profiles. Patient-reported outcome measures such as symptom side-effect lists need to be developed in a time-efficient manner to enable a rapid and full evaluation of new treatments and effective clinical management

objectiveThe aim of this study was to develop a set of TT-related symptoms and identify the optimal method for developing symptom lists. PATIENTS AND

methodsSymptoms from TT treatment in the context of Chronic Myeloid Leukaemia (CML), HER2-positive breast cancer, or Gastrointestinal Stromal Tumours (GIST) were identified through literature reviews, interviews with healthcare professionals (HCPs) and patients, and patient focus groups. The symptom set was then pilot tested in patients across the three cancer diagnoses: The number of items derived from each source (literature, patients, or HCPs) were compared.

resultsA total of 316 patients and 86 HCPs from 16 countries participated. An initial set of 209 symptoms was reduced to 61 covering 12 symptom categories. Patient interviews made the greatest contribution to the item set.

conclusionsSymptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment.

Indexed as

Patient Reported Outcome MeasuresFemaleHumansMaleMiddle AgedNeoplasms

Identifiers

PMID33165751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.